# Golimumab

## Simponi inj 50mg/0.5mL

| 藥物代碼 | ISIM |
| :--- | :--- |
| 適應症 | In combination w/ methotrexate for the treatment of moderate to severe active RA. Alone or in combination w/ methotrexate for active psoriatic arthritis \(PsA\). Treatment of active ankylosing spondylitis \(AS\). |
| 副作用 | Serious infections, malignancies, autoimmune disorders & autoantibodies, inj site reactions, new onset & exacerbations of psoriasis, immunogenicity, upper resp tract infection, nasopharyngitis, sepsis, increased ALT & AST; HTN, bronchitis, dizziness, sinusitis, flu, pharyngitis, rhinitis, pyrexia, oral herpes, paraesthesia. |
| 禁忌 | Canadian labeling: Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections \(eg, sepsis, tuberculosis, opportunistic infections\); moderate or severe heart failure \(NYHA class III/IV\) |
| 藥物保存方式 | 2-8 度C |
| 用法用量 | Dosing: Adult Ankylosing spondylitis: SubQ: 50 mg once a month. Psoriatic arthritis: SubQ: 50 mg once a month. Rheumatoid arthritis:SubQ: 50 mg once a month Ulcerative colitis:SubQ: Induction: 200 mg at week 0, then 100 mg at week 2, followed by maintenance therapy of 50-100 mg every 4 weeks. Dosing: Geriatric Refer to adult dosing |
| 肝功能異常 | 無需調整劑量  There are no dosage adjustments provided in manufacturer's labeling |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | PREGNANCY RECOMMENDATION: Contraindicated if combined with methotrexate. |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | BREASTFEEDING RECOMMENDATION: Contraindicated if combined with methotrexate. |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

